Spectral Medical Inc. (OTCQX: EDTXF) is engaged in the development and marketing of sepsis and septic shock treatments. Shares of the sepsis treatment company are diving 84%, during afternoon trading on Monday, October 3, 2016. Over the past three months, Spectral Medical Inc. has seen average daily volume of 59,261 shares. However, nearly 2.66 million shares or dollar volume of $532,000, has already exchanged hands through afternoon trading Monday.
Shares of Spectral Medical Inc. are crashing today after management released details on the company’s failed late-stage study. The company was on-track to become one of the first medical companies to have an FDA-approved treatment for sepsis. However, the late-stage study “did not meet the main goal of absolute reduction in mortality rate at 28 days, but did demonstrate beneficial treatment effects,” detailed Spectral Medical Inc. The company is still hopefully that changes can be made in order to get the treatment back on track for FDA approval by early 2018. Here is the complete press release detailing of the failed study:
Spectral Medical Inc. Press Release:
Oct 3 (Reuters) – Spectral Medical Inc. said its experimental treatment for sepsis – a common, oft-deadly complication of infection – failed a late-stage study, stymieing the company’s plans to bring to market the first FDA-approved device for the condition.
Sepsis occurs when the immune system goes into overdrive to fight infection or bacterial toxins, triggering a cascade of physiological changes that can lead to multiple organ failure and death.
Toronto-based Spectral Medical holds North American rights to a system developed by Japan’s Toray Industries Inc, designed to restore blood pressure and correct organ dysfunction by using an antibiotic to detoxify the blood.
Once the patient’s blood has been extracted, it is passed through two columns to remove a type of toxin, called an endotoxin, which is believed to be a major trigger for sepsis.
The trial did not meet the main goal of absolute reduction in mortality rate at 28 days but did demonstrate beneficial treatment effects, Spectral said on Monday.
“We proved beyond doubt that endotoxin is bad and taking it out is good,” and Spectral will discuss with the U.S. Food and Drug Administration the next steps, Chief Executive Paul Walker told Reuters.
A smaller-than-expected decrease in endotoxin adversely affected the rate of mortality reduction, he said.
If we can show “more columns take out more endotoxin, then I think we can get approved.”
There are no specific FDA-approved medicines for the treatment of sepsis, and there have been several high-profile clinical failures.
The leading cause of hospitalizations in the United States, it can result from a simple cut, routine surgery or infections associated with chronic disease.
Infants, the elderly and those with weakened immune systems are most at risk.
In extreme cases, a dramatic drop in blood pressure can lead to life-threatening septic shock, the category of patients Spectral is targeting.
Toray has been selling the product, the Toraymyxin system, in its home market since 1994 and through distributors in Europe since 2002. The system is also approved for use in Canada.
Still, data supporting use of the device is intensely debated, with trials conducted outside of Japan and Italy failing to prove its efficacy.
Walker expects Spectral Medical Inc. will now need to conduct an observational study to show that four columns, for example, will take out enough endotoxin to make a significant difference in mortality rate.
If all goes well, this could mean the device could win U.S. approval by early 2018, he said.